Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar 8:11:36-9.
doi: 10.1016/j.mmcr.2016.03.002. eCollection 2016 Mar.

Isavuconazole as salvage therapy for mucormycosis

Bianca Graves  1 , C Orla Morrissey  2 , Andrew Wei  3 , John Coutsouvelis  4 , Samantha Ellis  5 , Alan Pham  6 , Julian Gooi  7 , Michelle Ananda-Rajah  8
Affiliations

Isavuconazole as salvage therapy for mucormycosis

Bianca Graves et al. Med Mycol Case Rep. .

Abstract

Mucormycosis carries a high mortality rate with few therapeutic options available. We describe a man with pulmonary/splenic mucormycosis complicating hypoplastic myelodysplastic syndrome on a background of chronic kidney disease, who achieved a complete response with salvage isavuconazole therapy following intolerance of consecutive courses of liposomal amphotericin and posaconazole therapy.

Keywords: Isavuconazole; Mucormycosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
(A) CT chest at diagnosis demonstrating right lower lobe lesion with “reverse halo sign” and contiguous splenic involvement. (B) CT Chest following clinical deterioration post lobectomy demonstrating bilateral pleural effusions and peri-bronchial consolidation with a second splenic lesion. (C) CT Chest 11 weeks post isavuconazole therapy demonstrating resolution of the splenic lesions. Abbreviations: CT=computed tomography.
Fig. 2
Fig. 2
Histopathology of excised lung showing broad ribbon-like hyphae within necrotic tissue, consistent with mucormycosis (H&E ×40).
Fig. 3
Fig. 3
Isavuconazole levels (measured at pre-specified time intervals; as per manufacturer's instructions).
See this image and copyright information in PMC

References

    1. Petrikkos G., Skiada A., Lortholary O., Walsh T., Kontoyiannis Epidemiology and clinical manifestations of mucormycosis. Clin. Infect. Dis. 2012;54(Supp. 1):S23–S34. - PubMed
    1. A. Skiada, F. Lanternier, A.H. Groll, L. Pagano, S. Zimmerli, R. Herbrecht, O. Lortholary, G.I. Petrikkos, Diagnosis and treatment of mucormycosis in patients with haematological malignancies: guidelines from the 3rd European Conference on Infections in Leukaemia (ECIL 3), Haeamtologica 98 (4) (2013), pp. 492–504. - PMC - PubMed
    1. Astellas: FDA Advisory Committee Briefing Document: Isavuconium – Invasive Aspergillosis and Invasive Mucormycosis. 〈www.fda.gov/downloads〉
    1. F.M. Marty, J.R. Perfect, O.A. Cornely, et al., An open-label Phase 3 study of isavuconazole (VITAL): focus on mucormycosis. Presented at: ID week ASM. PA, USA 8–12 October 2014 (Abstract no. 824)
    1. Ananda-Rajah M., Kontoyiannis D. Isavuconazole: a new extended spectrum triazole for invasive mould infections. Future Microbiol. 2015;10(5):693–708. - PubMed

LinkOut - more resources